Newellis Inc (NUWE)

NUWE....14...🥳...Shorted down to .13 range but we have a Bullish Oversold Pincher Squeeze setting up here...with an Open Gap in the .40 range... Risk Reward Play...for a flip...

June 2026 Financing: Nuwellis closed a $6 million registered public offering.Warrant Triggers: The offering included Series C and Series D warrants exercisable at $0.30 per share. These warrants will become exercisable upon two conditions being met: stockholder approval and the effective date of a reverse stock split.Potential One-Time Reset: The terms of the Series C warrants include an exercise price reset provision that would adjust the warrant price based on the post-split trading activity.

$NUWE expanded its collaboration with a South Carolina health system to install Aquadex SmartFlow devices at a children’s hospital.
https://www.rapidticker.com/news/nuwe-nuwellis-expands-collaboration-with-major-557d9b

$NUWE The borrow rate increased by 320 percent in 11 days

Borrow rate increased again.

Golden cross over on the 15 minute chart.

NUWE, Was even $15.4 last July. LOL!

NUWE, from $6.95 to $0.17, amazing run!

NUWE, Doing big R/S, then diluting largely, then repeat, again and again.

Nuwellis Shares Sink After Pricing $6 Million Equity and Warrant Offering (NUWE)June 5, 2026 10:29 AM
IH Market News Nuwellis Inc. (NASDAQ:NUWE) shares plunged 65.2% in premarket trading on Friday after the medical technology company announced a heavily discounted public offering designed to raise approximately $6 million. The financing was priced at $0.30 per share, significantly below recent market levels, triggering a sharp selloff as investors assessed the potential impact of dilution. Company Issues 20 Million Shares and Warrants Under the terms of the transaction, Nuwellis will issue 20 million shares of common stock together with Series C and Series D warrants. The offering is expected to generate gross proceeds of approximately $6 million before deducting placement agent fees and other related expenses. Management has not disclosed a detailed allocation of proceeds but is expected to use the funds to support ongoing corporate and operational requirements. Warrants Carry Five-Year Exercise Period Both the Series C and Series D warrants have an exercise price of $0.30 per share. The warrants will become exercisable for a five-year period following shareholder approval and the completion of a reverse stock split, as required under Nasdaq regulations. The structure gives investors the opportunity to purchase additional shares in the future at the same price as the current offering. Series C and Series D Warrants Include Special Features The financing package includes Series C warrants covering up to 60 million common shares and Series D warrants covering up to 20 million shares. Series C warrants contain a one-time adjustment mechanism linked to any future reverse stock split implemented by the company. Meanwhile, the Series D warrants include a zero-cash exercise feature, allowing holders to receive shares without making an additional cash payment under specified conditions. Existing Warrants Repriced Through Separate Agreement Alongside the public offering, Nuwellis entered into private agreements with certain holders of previously issued warrants. Under those arrangements, the exercise price of existing warrants will be reduced to $0.30 per share, aligning them with the pricing of the new offering. The repricing transactions remain subject to shareholder approval before they can take effect. Financing Led by Ladenburg Thalmann Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for the offering. The transaction represents a significant capital-raising effort for the company as it seeks to strengthen its financial position and support future operations. Focus Remains on Cardiorenal Medical Technologies Nuwellis develops medical technologies designed for patients suffering from cardiorenal conditions, a category that includes interconnected heart and kidney disorders. The company continues to focus on expanding the adoption of its therapeutic solutions while pursuing initiatives aimed at supporting long-term growth. However, the size of the offering, its discounted pricing and the large number of attached warrants raised concerns among investors, contributing to the sharp decline in the stock following the announcement. Nuwellis stock price Original: Nuwellis Shares Sink After Pricing $6 Million Equity and Warrant Offering (NUWE)

Any word from Management how they are going to address the disastrous decline in the pps that has affected shareholders in the last year?

NUWE.......................................https://stockcharts.com/sc3/ui/?s=NUWE&p=w&b=5&g=0&id=p86431144783

Nuwellis (NUWE) stock is surging in premarket trading on January 27, 2026, primarily driven by the announcement of a new U.S. patent for advanced safety mechanisms in its blood filtration systems. The patent strengthens their intellectual property portfolio for the Aquadex system, indicating potential for increased adoption in pediatric and fluid management care

NUWE.....................................https://stockcharts.com/sc3/ui/?s=NUWE&p=w&b=5&g=0&id=p86431144783

NUWE,, there is a pump on this one,,, might be good

Great short today Tradezero down to $3.25 bottomless pit

$4.20s on news 

NUWE 9/15/2025: Nuwellis Will Be Issued U.S. Patent Number 12,415,021 on 9/16/2025 Titled "EXTRACORPOREAL BLOOD FILTERING MACHINE AND METHODS (FOR TREATMENT OF FLUID OVERLOAD)".
Nice NUWE after-hours interest yesterday showed how small float like this can blow FAST...
GLTA

NUWE tanks now on $3m news?

$5.60 to $6.95 look to dump your shares quickly 

Scanner says watch for a pump

NUWE $8.8m rev, and only $593k Market Cap?!
Holding it down so bigger pop Friday earnings call?

NUWE hit earnings all but Q4 so what you think for earnings call this 8/12 ?

Good news, shutting down an obsolete trial, saving the company 4 million $

Would be great to see NUWE back to back news. Could drive another 200%.GLTA

NUWE sweet move on that a/h news 😃

NUWE offering closed https://ih.advfn.com/stock-market/NASDAQ/newellis-NUWE/stock-news/96217141/nuwellis-announces-closing-of-5-0-million-underwr

Any word from Management how they will increase shareholder value?

How about stop the bleeding?

$1.40s + 20% low float 1m pump time news was good higher rate with Medicare aid so revenues will be higher this quarter 

$1.30 regained complainace few weeks back and device reimbursement Medicare/aid

NUWE.........................https://stockcharts.com/h-sc/ui?s=NUWE&p=W&b=5&g=0&id=p86431144783

restart soon

$2.25- + 23% ..2:40- 2.83 zone of interest breaks 2.83 gets interesting 

NUWE...................................https://stockcharts.com/h-sc/ui?s=NUWE&p=W&b=5&g=0&id=p86431144783

$2.30 + 24% NUWE 10k out reimbursement from Medicare/aid 400% increase 

$NUWE )2.18 + 20% Looks good a flip to $4 if gets going 

NUWE, 10Q due 11/11

Will see $8s here in time .Nice dip $1.60s today added ..this one takes off again after Nov 4th news  Medicare Medicaid pay quadruples on Jan 1st.. 4x 
with the payment rate increasing to $1,639 a day from $413, Nuwellis said Monday in a statement.

The reassignment recognizes the effectiveness of the therapy for the treatment of fluid overload in heart

Have buys stops and short cover over $3.24. 

Close above $4

Thank you for 2.55. Loaded

Circuit Breaker $3.29

1.9 float?  

Back to the $2s heck was a $20 stock not long ago

Is this a good long term buy?

nuwe.........................https://stockcharts.com/h-sc/ui?s=NUWE&p=W&b=5&g=0&id=p86431144783

$1.80 + 25% Time to pump this low floater again next up 1.85- 1.99
2.14- 2.27

2.40-2.84

Haven’t been able to absorb offering since August 23 ..what’s the next catalyst ?

sale of 496,901 shares of the Company’s common stock at a price of $1.8450 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules.
In addition, in a concurrent private placement, the Company will issue to the investors warrants to purchase up to 496,901 shares of common stock. The warrants have an exercise price of $1.72 per share, will be exercisable immediately following the date of issuance and will

Buy high sell low

big catalyst coming up for this low floater
New Evidence on Aquadex Ultrafiltration Therapy to be Presented at HFSA 2024 Conference taking place September 27-30, 2024
https://ir.nuwellis.com/news-releases/news-release-details/new-evidence-aquadex-ultrafiltration-therapy-be-presented-hfsa

NUWE 52w low… $1